



Port Said University
Faculty of Science
Chemistry & Biochemistry Department



Biochemical Evaluation Of
7-Hydroxy-2-Oxo-2H-Chromene-3-
Carboxylic Acid P-Tolylamide
As Antitumor

Presented by

Asmaa Fawzy Fawaz

Supervised by

Prof. Dr. Ibrahim Mohyeldin

Presented to

Port Said University

Faculty Of Science

Biochemistry Department

4th level

2016

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ رَبِّ اشْرَحْ لِي صَدْرِي وَيَسِّرْ
لِي أَمْرِي وَأَحْلِلْ عُقْدَةً مِّنْ
لِّسَانِي يَفْقَهُوا قَوْلِي

سورة طه

صدق الله العظيم

Acknowledgments

First of all, limitless gratitude to **God**, most merciful, who blesses my effort, shows me the way and enables me to present this work in an acceptable style.

Special thanks to my supervisor *Prof. Dr. Ibrahim MohyEldin (Prof. of organic chemistry, Faculty of science, Port Said University)* for giving me the honor of working under his supervision, supplying the equipment and facilities required to accomplish this work.

Also I would like to express my thanks to *Dr. Mohamed Elbehery (Assistant lecturer of Biochemistry, Faculty of science, Port Said University)* for his support, exertion continuous encouragement and advices during the work.

I would like to give my special thanks to my family for patience and moral support they provided throughout my research work.

Table of content

Chapter1:-

I. Introduction.....	1
I.1.Cancer.....	1
I.1.1.CauseCancer.....	2
I.1.2.Development of Cancer.....	4
I.1.3.Genetics of Cancer.....	5
I.2.Tumers.....	8
I.2.1.Benign.....	8
I.2.2.Malignant.....	9
I.3 Selected Cancers.....	11
I.4.Some Causes of Cancer.....	22
I.4.1.Environmental Factors.....	22
I.4.2.Viruses and Cancer.....	23
I.5.Some general signs and symptoms of Cancer.....	24
I.6.Cancer Therapy.....	27
I.6.1.Surgery.....	27
I.6.2.Chemotherapy.....	28
I.6.3.Radiation Therapy.....	30
I.7.Ehrlich ascites carcinoma.....	31
I.8.Biological activity of coumarin derivatives.....	34

Chapter 2:-

II.Material& Method.....	38
II.1.materials.....	38
II.2.Methods.....	40
II.2.1.Properties of ethyl-7-hydroxy-2-oxo-2H-chromene-3-carboxylate.....	44
II.2.2.Properties of 7-hydroxy-2-oxo -N-(p-tolyl) -2H-chromene-3-carboxamide.....	46
II.2.3.Properties of potassium(Z)7oxid -2-oxo -N-(p-tolyl) -2H-chromene-3-carboxamide.....	48
II.2.4.In vitro studies.....	49
II.2.4.1.Determination of potential cytotoxicity of synthetic Compound on human cancer cell line.....	51
II.2.5.In vivo studies.....	53
II.2.5.1.Toxicity studies.....	53

Chapter 3:-

III.Result&Discussion.....	54
III.1.In vitro studies.....	54
III.2.In vivo studies.....	58
III.3.Discussion.....	59

Chapter 4:-

IV.References.....	60
---------------------------	-----------

List of figure

<i>Figure (1)</i>	the difference between normal cell division and cancer cell division	3
<i>Figure (2)</i>	stage of cancer	5
<i>Figure (3)</i>	Differences between benign and malignant	10
<i>Figure (4)</i>	Symptoms of leukemia	12
<i>Figure (5)</i>	Cancer surgery	27
<i>Figure (6)</i>	Chemotherapy drug	28
<i>Figure (7)</i>	Radiation Therapy	30
<i>Figure (8)</i>	Ehrlich Ascites Tumors in Mice	33
<i>figure(9)</i>	application of coumarins	34
<i>Figure (10)</i>	Trypan blue dye	49
<i>Figure (11)</i>	cytotoxicity of prepared compound against cell line MCF-7	54
<i>Figure (12)</i>	cytotoxicity of prepared compound against cell line HEPG-2	55
<i>Figure (13)</i>	cytotoxicity of prepared compound against cell line HCT	56
<i>Figure (14)</i>	cytotoxicity of prepared compound against cell line PC3	57

List of table

Table (1)	Evaluation of cytotoxicity of prepared compound against cell line MCF-7	54
Table (2)	Evaluation of cytotoxicity of prepared compound against cell line HEPG-2	55
Table (3)	Evaluation of cytotoxicity of prepared compound against cell line HCT.	56
Table (4)	Evaluation of cytotoxicity of prepared compound against cell line PC3	57
Table (5)	The IC₅₀ Values	58

Abbreviation

ALL	Acute lymphoblastic leukemia
CLL	Chronic lymphocytic leukemia
AML	Acute Myeloid Leukemia
CML	Chronic Myeloid Leukemia
NHL	Non-Hodgkin's Lymphoma
NMSC	Non Melanoma Skin Cancer
IA	Intra-arterial
IP	Intraperitoneal
IV	Intravenous
H-2	Histocompatibility antigen
EAC	Ehrlich Ascites Carcinoma
S.C.	Subcutaneous injection
RNA	Ribo Nucleic Acid
ATP	Adenosine-Triphosphate
GSH	Glutathione
NK	Natural killer cells
EACF	Ehrlich Ascites Carcinoma Factor

HIV	Human Immunodeficiency Virus
HSV	Herpes Simplex Virus
Hi-Media	Hinton agar medium
DMSO	Dimethyl sulfoxide
S.aureus	Staphylococcus aureus
EDTA	Ethylenediamine Tetraacetic Acid
RPMI-1640	Roswell Park Memorial Institute
HCT	Human colon cancer cell line
MCF-7	Human breast carcinoma cell line
HepG-2	Human hepatocellular carcinoma cell line
PC-3	human prostate cancer cell lines
IR spectra	Infra-red spectra
NMR spectra	Nuclear Magnetic Resonance
MHZ	Megahertz
TMS	Transcranial magnetic stimulation
MS	Mass spectra
m.p	Melting point

ppm	parts per million
FBS	Fetal Bovine Serum
SRB	Sulphorhodamine-B
TCA	Trichloroacetic acid
O.D	Optical density= Survival fraction
ELISA	Enzyme Link immune sorbent assay
LD	Lethal dose
IC	inhibitory concentration
HCC	hepatocellular carcinoma
PIP	Piperidin
DMF	Dimethylformamide

